Díaz GEJ, Sánchez AR, Santibañez SV

Language: Spanish
References: 15
Page: 290-295
PDF size: 264.28 Kb.

ABSTRACT

Diabetic neuropathy is the most common neurological complication in patients with diabetes; it is estimated that 16% of people with diabetes present this condition. Of all neuropathies in diabetic patients, 75% fall under the category of "distal symmetric polyneuropathy" or DSPN; peripheral neuropathy can encompass any disorder of the peripheral nervous system, including radiculopathies and mononeuropathies. Among the clinical manifestations, one of the primary symptoms is pain, described as burning or stabbing, which can either improve or worsen, leading to walking difficulties. It is important to emphasize that prevention is the number one method for managing neuropathy, focusing on glucose control and lifestyle modifications. According to evidence, duloxetine is recommended as the first-line pharmacological treatment, followed by pregabalin as the second line, and tapentadol as the third line.

REFERENCES

1. Feldman EL. Management of diabetic neuropathy. UpToDate. 2022. Available in: https://www.uptodate.com/contents/management-of-diabetic-neuropathy?search=neuropatia%20diabetica&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1

2. Price R, Smith D, Franklin G, Gronseth G, Pignone M, David WS et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN Guideline Subcommittee. Neurology. 2022; 98 (1): 31-43. doi: 10.1212/WNL.0000000000013038.

3. Chang MC, Yang S. Diabetic peripheral neuropathy essentials: a narrative review. Ann Palliat Med. 2023; 12 (2): 390-398.

4. Feldman EL. Pathogenesis of diabetic polyneuropathy. UpToDate. 2022. Available in: https://www.uptodate.com/contents/pathogenesis-of-diabetic-polyneuropathy?search=neuropatia%20diabetica&source=search_result&selectedTitle=5~150&usage_type=default&display_rank=5#H1

5. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA et al. Diabetic neuropathy: a position statement by the american diabetes association. Diabetes Care. 2017; 40 (1): 136-154. doi: 10.2337/dc16-2042.

6. Rutkove SB. Overview of polyneuropathy. UpToDate. 2022. Available in: https://www.uptodate.com/contents/overview-of-polyneuropathy?search=neuropatia%20diabética&source=search_result&selectedTitle=12~150&usage_type=default&display_rank=12

7. Volmer-Thole M, Lobmann R. Neuropathy and diabetic foot syndrome. Int J Mol Sci. 2016; 17 (6): 917. doi: 10.3390/ijms17060917.

8. Baum P, Toyka KV, Blüher M, Kosacka J, Nowicki M. Inflammatory mechanisms in the pathophysiology of diabetic peripheral neuropathy (DN)-new aspects. Int J Mol Sci. 2021; 22 (19): 10835.

9. Dohrn MF, Winter N, Dafotakis M. Causes, spectrum, and treatment of the diabetic neuropathy. Nervenarzt. 2020; 91 (8): 714-721.

10. Gupta M, Knezevic NN, Abd-Elsayed A, Ray M, Patel K, Chowdhury B. Treatment of painful diabetic neuropathy-a narrative review of pharmacological and interventional approaches. Biomedicines. 2021; 9 (5): 573.

11. Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019; 5 (1): 41.

12. Cernea S, Raz I. Management of diabetic neuropathy. Metabolism. 2021; 123: 154867.

13. Qureshi Z, Ali MN, Khalid M. An insight into potential pharmacotherapeutic agents for painful diabetic neuropathy. J Diabetes Res. 2022; 2022: 9989272.

14. Staudt MD, Prabhala T, Sheldon BL, Quaranta N, Zakher M, Bhullar R et al. Current strategies for the management of painful diabetic neuropathy. J Diabetes Sci Technol. 2022; 16 (2): 341-352.

15. Karonova T, Stepanova A, Bystrova A, Jude EB. High-dose vitamin d supplementation improves microcirculation and reduces inflammation in diabetic neuropathy patients. Nutrients. 2020; 12 (9): 2518.